Assay of angiogenesis
Angiogenesis and pharmacological therapy
Since Judah Folkman postulated in 1971 (N Engl J Med, 21, 1182-86) that inhibition of angiogenesis can limit the growth of solid tumors by cutting off the supply with nutrients and oxygen, the discovery and development of new anti-angiogenic drugs has attracted much attention in medical and pharmacological research.
The therapeutic application of angiogenic inhibitors became a promising concept in controlling "angiogenic diseases" and at present numerous compounds are being studied in clinical trials (click here for examples).
Anti-angiogenic effectors can be differentiated according to the target, including inhibitors of proteases, inhibitors of cell proliferation and migration, antagonists of angiogenic growth factors, integrin antagonists and effectors with non-specific mechanisms.
The identification of a potential anti-angiogenic effector requires a reliable assay.
We have established an in vitro assay of angiogenesis to identify the anti- or pro-angiogenic potential and cytotoxicity of compounds. The assay of angiogenesis utilizes human dermal microvascular endothelial cells and we have defined criteria for a software-supported image quantification (SSIQ) for analyzing the effects of compounds on angiogenesis.
For further information please contact: info@amplab.de